Skip to content
Biodatica
Start free

Imunon

Orlando, Florida

OncologyPhase IIIListed · IMNN

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

3d agoTrial registeredJul 16, 2026Source filing (opens the source filing in a new tab)

Momentum

88no change

Momentum 88 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Jul 9, 2025

    Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma · RECRUITING · sponsor: Imunon · Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

    ClinicalTrials.gov · NCT06915025 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Jan 18, 2022

    Cancer Debulking, Enlarged Uterus, Fibroid Uterus, Adnexal Mass · TERMINATED · sponsor: Washington University School of Medicine · Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy

    ClinicalTrials.gov · NCT05017246 (opens the source filing in a new tab)

  3. Grant

    UG1 · $1.6M · non-dilutive

    Mar 5, 2019

    WASHINGTON UNIVERSITY · PI BARTLETT, NANCY L · NCI · award ends Feb 29, 2032 · WASHINGTON UNIVERSITY / SITEMAN CANCER CENTER LEAD ACADEMIC SITE

    NIH RePORTER · NIH RePORTER 11289863 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Apr 2, 2013

    Grade 3a Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Refractory Follicular Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: National Cancer Institute (NCI) · Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

    ClinicalTrials.gov · NCT01849263 (opens the source filing in a new tab)

  5. Trial

    Study registered

    Aug 1, 2003

    Ovarian Neoplasms · COMPLETED · sponsor: Susan Lutgendorf · Biobehavioral-Cytokine Interactions in Ovarian Cancer

    ClinicalTrials.gov · NCT01113112 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources